Tested Applications
| Positive IP detected in | L02 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunoprecipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
12091-1-AP targets G0S2 in WB, IHC, IF, IP, CoIP, ChIP, ELISA applications and shows reactivity with human, mouse samples.
| Tested Reactivity | human, mouse |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
CatNo: Ag2731 Product name: Recombinant human G0S2 protein Source: e coli.-derived, PGEX-4T Tag: GST Domain: 1-103 aa of BC009694 Sequence: METVQELIPLAKEMMAQKRKGKMVKLYVLGSVLALFGVVLGLMETVCSPFTAARRLRDQEAAVAELQAALERQALQKQALQEKGKQQDTVLGGRALSNRQHAS Predict reactive species |
| Full Name | G0/G1switch 2 |
| Calculated Molecular Weight | 11 kDa |
| GenBank Accession Number | BC009694 |
| Gene Symbol | G0S2 |
| Gene ID (NCBI) | 50486 |
| RRID | AB_2877824 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P27469 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
G0S2 is G0/G1 switch protein 2. It is an all trans- retinoic acid (RA) target gene. G0S2 promotes apoptosis by binding to BCL2, hence preventing the formation of protective BCL2-BAX heterodimers.
Protocols
| Product Specific Protocols | |
|---|---|
| IP protocol for G0S2 antibody 12091-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
G0S2 Polyclonal Antibody (12091-1-AP) — Citation Summary
This antibody has 23 total citations. It appears in journals including Cancer Research, Nature Communications, Journal of Clinical Investigation, Journal of Experimental & Clinical Cancer Research, Cell Death & Disease, Pharmacological Research, NPJ Precision Oncology, Cell Reports, Molecular Metabolism, Communications Biology, Journal of Clinical Endocrinology & Metabolism, and Journal of Translational Medicine. Research fields span oncology (pancreatic, breast, lung, head-and-neck, and liver cancer), lipid metabolism and adipocyte biology, metabolic/obesity disorders, immunology, and hepatotoxicity studies. Applications cited include WB, IHC, IF, IP/CoIP, and ChIP across human, mouse, and rat samples.
| Species | Application | Title |
|---|---|---|
Cancer Res Bcl-xL enforces a slow-cycling state necessary for survival in the nutrient-deprived microenvironment of pancreatic cancer. | ||
Cancer Res An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation.
| ||
Nat Commun Single-cell analysis reveals fibroblast heterogeneity and myeloid-derived adipocyte progenitors in murine skin wounds. | ||
J Clin Invest Identification of lysosomal lipolysis as an essential noncanonical mediator of adipocyte fasting and cold-induced lipolysis | ||
J Exp Clin Cancer Res Lipolytic inhibitor G0S2 modulates glioma stem-like cell radiation response.
| ||
Cell Death Dis Methyl-CpG-binding domain protein 2 contributes to renal fibrosis through promoting polarized M1 macrophages.
|

